Molecular imaging enjoys progress on multiple fronts

July 1, 2008 Diagnostic Imaging. Molecular imaging enjoys progress on multiple fronts James Brice -------------------------------------------------------------------------------- From a pivotal study that may broaden Medicare's acceptance of FDG-PET to Raman spectroscopic techniques that promise a 1000-fold improvement in sensitivity compared with fluorescence imaging, the first half of 2008 will be remembered for fruitful molecular imaging research. As of June 1, the Centers for Medicare and Medicaid Services was weighing the evidence from an application to grant routine Medicare coverage for FDG-PET to diagnose, stage, restage, and evaluate patients for suspected recurrence of brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers. Approval could mean the procedures would no longer be subject to monitoring through the National Oncologic PET Registry, a research effort deemed necessary in 2005 to study their impact on patient management.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC